...
首页> 外文期刊>Australian and New Zealand Journal of Obstetrics and Gynecology >A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy.
【24h】

A randomised trial of oral versus vaginal administration of misoprostol for the purpose of mid-trimester termination of pregnancy.

机译:孕三月中期妊娠中期孕中期的口服与阴道施用的随机试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A prospective randomised controlled trial was undertaken to compare the efficacy of two routes of administration, oral versus vaginal, of the prostaglandin E1 analogue misoprostol (Cytotec) to effect termination of pregnancy in the mid-trimester. Fifty-five women were recruited into the trial; 26 to receive all doses orally and 29 via the vaginal route. The dosing regimen was 400 microg as the initial dose followed by a second dose of 200 microg two hours later and then four-hourly 200 microg doses until delivery or 32 hours from commencement of treatment. If delivery had not been effected by the last dose of misoprostol, a Syntocinon infusion was started synchronously Misoprostol administered vaginally was significantly more effective than when administered orally as judged by induction-to-delivery interval and also the need or otherwise to augment therapy with a Syntocinon infusion. The average induction-to-delivery interval was 17.5 hours in the vaginal group compared to 33 hours in the oral group (p = 0.0003). The percentages of women who delivered at 24 and 48 hours were 93% and 100% in the vaginal administration group and 19% and 70% in the oral administration group (p < 0.05). No significant differences in complication rates or side effects were noted between the two groups
机译:进行了预期随机对照试验,以比较两种给药途径,口服与阴道,前列腺素E1类似物米索前列醇(Cytotec)的疗效,以影响妊娠期妊娠期的妊娠。招募五十五名妇女审判; 26以口服所有剂量和阴道途径接受。当剂量方案为400 microg,因为初始剂量随后是两小时后的第二剂200微量量,然后四小时200微量镜剂量直至递送或32小时从开始处理32小时。如果通过最后剂量的米索前列醇进行递送,则同步氧代莫冬醇的杀虫剂输注比通过诱导 - 递送间隔判断,同时给予口服时,显着更有效,并且还需要或以其他方式增强治疗纯度输注。在阴道基团中,平均诱导至递送间隔为17.5小时,而在口腔基团中为33小时(P = 0.0003)。在24和48小时交付的妇女百分比在阴道给药组中为93%和100%,口服给药组中的19%和70%(P <0.05)。两组之间没有发现并发症率或副作用的显着差异

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号